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Abstract 
On 9 December 2019, the Institute for Clinical and Economic Review (ICER) released its final evidence report to establish the value of 
oral semaglutide (Novo Nordisk) for Type 2 diabetes (T2DM). A key element in this report was the development of a lifetime cost 
effectiveness microsimulation model based on a small sample of NHANES diabetes respondents. The model contrasted oral semaglutide 
added to current antihyperglycemic treatment for T2DM. The purpose of the model was to estimate outcomes that included life years 
(LYs) gained, an estimate of equal value life years gained (evLYGs), QALYs gained, clinical events, cost per major adverse cardiovascular 
events (MACE) avoided and total costs for each intervention over a lifetime time horizon. Previous commentaries in INNOVATTIONS in 
Pharmacy have provided detailed critiques of the ICER modeling framework. While this model differs from previous ICER models, the 
result is still a framework that constructs a so-called evidence base that fails the demarcation test. It is best described as pseudoscience. 
The model creates, by assumption, an imaginary world. The claims made for oral semaglutide by ICER should not be taken seriously by 
health care decision makers.  The purpose of this commentary is to point to the limitations of the model with particular reference to 
the utility metrics employed, the resulting claims for quality adjusted life years (QALYs) and consequent recommendations for price 
discounting and affordability.  
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Introduction 
The construction of assumption driven imaginary worlds to 
support incremental cost-per-QALY claims for pricing and 
access recommendations is the hallmark of the Institute for 
Clinical and Economic Review’s (ICER) business model. ICER’s 
evidence report on oral semaglutide for Type 2 Diabetes 
(T2DM) (Rybelsus, Novo Nordisk) follows this model. The  
evidence report, released on 1 November 2019, together with 
ICER’s response to public comments, was followed by 
 the formal ICER evidence presentation and voting on  
14 November 1 2. The final evidence T2DM report with meeting 
summary was released on 9 December 2019 3. 
 
The primary aim of the ICER model, utilizing an individual, 
Monte Carlo based-microsimulation was to estimate the 
lifetime cost effectiveness of oral semaglutide added to current 
antihyperglycemic treatment for T2DM. The model was chosen 
because of the complexity of co-morbidities in Type 2 diabetes 
populations. The model outcomes included life years gained, 
quality adjusted life years (QALYs), clinical events, cost per 
major adverse cardiovascular event (MACE) avoided and total 
costs for each intervention over a lifetime treatment horizon.  
 
The comparisons modeled involved oral semaglutide added to 
current antihyperglycemic treatment versus: (i) ongoing 
background antihyperglycemic treatment (e.g., metformin with  
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or without sulfonylureas), (ii) sitagliptin (Januvia, Merck), (iii) 
empagliflozin (Jardiance, Boehringer Ingelheim), and (iv) 
liraglutide (Victoza, Novo Nordisk); comparators (ii), (iii), and 
(iv) were also added to ongoing antihyperglycemic treatment. 
The target hypothetical population was adults with T2DM  
with inadequate glycemic control although receiving 
antihyperglycemic therapy.  The range of modeling options 
considered and the various proposed endpoints, should not be 
taken as indicative of the merits of the ICER reference case 
model. It is an entirely imaginary framework which fails, as will 
be pointed out in this commentary, to meet the standards of 
normal science. This failure is made even more egregious, as 
detailed here, in the absence of any consideration of the need 
to meet fundamental measurement standards. 
 
Even though The base-case modelled outcomes were 
considered by ICER to be ‘highly uncertain’ reflecting both 
variance in the model assumptions (input parameters and the 
risk equations) as well as uncertainties from the clinical network 
meta-analyses, ICER presented a range of outcome claims.  
Imaginary lifetime mean total cost for oral semaglutide was 
estimated at $295.000 with other comparator costs ranging 
from $250,000 to $305,000. Imaginary lifetime QALYs were 
estimated at 4.09 for oral semaglutide with a range from 3.63 
to 3.97 for the comparators. Incremental cost per QALY gained 
was modeled in the range $110,000 for oral semaglutide plus 
background treatment at versus background treatment alone, 
$140,000 for sitagliptin plus background treatments and 
$480,000 for empagliflozin plus background treatment. 
Compared to liraglutide plus background treatment oral 
semaglutide was cost saving. 
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The imaginary world of ICER also generated recommendations 
for oral semaglutide discounting. While, as argued in this 
commentary, these certainly should not be taken seriously, 
ICER suggested a value-based benchmark price range that 
would achieve incremental cost-effectiveness between 
$100,000 and $150,000 per QALY gained. These are discounts 
between 32% and 36% from list price (WAC),  
 
ICER, in discussing the limitations to its imaginary world 
modelling, pointed to: (i) the complexity of T2DM management; 
(II) unrepresentativeness of the NHANES sample for the T2DM 
subpopulation of interest as the basis for the microsimulation; 
(iii) lack of data on long-term follow-up for cardiovascular and 
renal outcomes including adherence; (iii) lack of concordance 
with clinical guidelines (‘they have been muted for this modeling 
exercise’); and (iv) lack of a ‘single comprehensive source of 
health-related quality of life inputs’ (discussed in more detail 
below). Given these limitations a reasonable question is why 
ICER would ‘endeavor to persevere’ with constructing an 
imaginary world 4. Presumably, this was dictated by the 
commitment to the ICER business model.  
 
This commentary has a number of objectives:  
 
 to point to the lack of a mandate in the US for ICER 
modeling;  
 to make the case, following  from previous 
commentaries, that the ICER lifetime reference case 
model lacks scientific credibility and should be seen as 
pseudoscience;  
 to make the point that, even if one accepts ICER 
imaginary reference case models, the ICER model is 
only one of a possible multiverse of models where 
each purport to provide approximate information (or 
disinformation) for formulary decisions; 
 to consider the failure of ICER to recognize the 
importance of meeting the standards of fundamental 
measurement in modeling evaluable claims for 
therapy options: 
 the misuse of utility scores in creating QALYS by 
assuming they have interval measurement properties 
while they are in fact ordinal manifest scores 
 to emphasize the importance of the Rasch model 
framework as the only approach to creating outcomes 
instruments that meets the standards of fundamental 
measurement; 
 to consider, as a case study the limitations of the  
widely accepted Audit of Diabetes Dependent QoL 
(ADDQoL) instrument in its failure to meet 
fundamental measurement standards; 
 to abandon QALYs as a meaningful metric for 
evaluating value claims 
 to consider whether manufacturers and other 
stakeholders should continue to  engage with ICER; 
and  
 to consider options for evaluating the introduction of 
oral semaglutide that focus on, not imaginary 
constructs, but on empirically evaluable claims.  
 
This commentary follows from a Part 1 commentary on the ICER 
final evidence report for JAK inhibitors 5. As a number of the 
arguments present are identical to those in the previous 
commentary, references are made rather than repeating the 
same arguments. 
 
In achieving these objectives, it should be emphasized that 
deconstructing an ICER incremental cost-per-QALY model does 
not imply support for the imaginary world meme 6. While the 
construction of imaginary worlds has been the mainstay of 
health technology assessment claims over the past 30 or more 
years, ICER’s plea that it is applying ‘state of the art; techniques’ 
is both misleading and irrelevant. Constructing imaginary 
evidence, as considered in more detail below, is not how 
science advances, particularly when the claims for QALYs are 
nonsensical. They fail the axioms of fundamental 
measurement. They should be abandoned. Rather, as in drug 
development, technology assessment should be a process of 
discovery, not a process of fabricating one imaginary construct 
after another with various non-evaluable claims and value 
judgments. ICER, as noted in previous commentaries is an 
irrelevant and unnecessary distraction; unfortunately, against 
all common sense ICER, will be determined to persevere in 
marketing imaginary models and recommendations.  
 
Mandate: ICER is not NICE 
Previous commentaries have made the point that ICER is not an 
agency such as the National Institute for Clinical Excellence 
(NICE) in the UK or the Pharmaceutical Benefits Advisory 
Committee   (PBAC) in Australia. It is not even NICE-lite which is 
apparent comparing ICER’s perceived mission and the range of 
activities allocated to NICE. Most significantly, ICER has no 
legislative role. Its role as health technology assessment arbiter 
is assumed not anointed. Its recommendations have no 
regulatory impost; unless agencies are prepared to take its 
recommendations at face value rather than deconstructing 
claims which have no scientific merit. 
 
Certainly, ICER mimics NICE and the PBAC (and others) in 
following a reference case or imaginary world paradigm. It has 
taken on board the health technology assessment meme, 
considered by those who believe in the construction of lifetime 
imaginary worlds to create ‘approximate information’ or 
‘approximate disinformation’, as the state of the art or dogma 
in health technology assessment. The difference is that NICE, 
the PBAC and others ‘require’ the construction of imaginary 
worlds. Manufacturers submit their imaginary world, it is 
challenged by academic assessment groups with decades of 
experience in dissecting these fairyland constructs, and an 
agreement on an imaginary world and its value 
recommendations made. ICER does not do this: it creates its 
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own imaginary world. Certainly, stakeholders can review but in 
the last resort, ICER wins out. 
 
If the arguments presented here are accepted, then ICER may 
continue, but under a cloud. How can manufacturers and 
patient interest groups continue to pay any attention to ICER 
when its ‘recommendations’ are a fabrication.  ICER may 
continue to create patently imaginary constructs which suffer 
from fatal methodological and measurement flaws and have 
the temerity, after a rather odd voting scene, argue for price 
discounts and access limitations. It is, perhaps time to move on. 
 
The Standards of Normal Science 
Again, previous commentaries have pointed to NICE standing 
aside from the standards of normal science; the focus on 
evidence and the discovery of new facts. Instead, ICER, like 
NICE, recycles existing ‘facts’ (assumptions) and creates an 
imaginary world to support value claims. This is, as noted in 
previous commentaries, nonsensical. If a new product or device 
is to be admitted to formulary and a price negotiated, we don’t 
need fabricated imaginary value claims, but evidence for the 
impact of the product on a target treating population. At 
launch, we may only have clinical data. This may be sufficient to 
propose cost-outcome claims, but these must be credible, 
evaluable and replicable. If these data points are not to hand 
then, rather than creating an imaginary modeled world, the 
focus should be on claims assessment and feedback to a 
formulary committee. We need to provide the framework for 
new discovery; the process of hypothesis testing, conjecture 
and refutation, that has been in place since the scientific 
revolution of the 17th century. Not, it must be emphasized, a 
retreat to a medieval world where the search for new facts is 
discouraged; subsumed in an acceptance of imaginary and 
unsupported claims for therapeutic impact and value. 
 
Assumptions 
The ICER claim to fame is the ability to construct or fabricate an 
imaginary world that sets the stage for value impact over 10, 20 
or 30 years in the future. The point is, and this goes back to 
Hume’s (David Hume 1711 – 1776) induction problem; we 
cannot ask clients in health care to believe in models 
constructed on the belief that prior assumptions will hold into 
the future. It is logically indefensible. Certainly, models can 
involve assumptions but the difference is that the worth of the 
assumptions can be assessed if the model is designed to 
generate evaluable, credible and replicable claims. 
 
Add to this the assumption that utility number lines have 
interval properties. Rejecting this assumption, for which there 
is no basis in instrument development, means that QALYs, the 
aggregation of QALYS over a modeled lifetime and consequent 
incremental cost-per-QALY claims have no meaning.  
 
Utilities and QALYs 
As detailed below, the utility metrics that ICER and other health 
technology model builders use to construct QALYs and cost-
per-QALY claims, fail to meet the axioms of fundamental 
measurement theory, including the axioms of conjoint 
simultaneous measurement where the construct or object to 
be measured is psychological or non-physical. Conjoint 
simultaneous measurement, and its modified version in Rasch 
measurement theory, provide the tools for detecting, if they 
exist, measurement structures that meet the criteria for 
fundamental measurement. Unfortunately, few patient 
reported outcomes (PRO) measures meet these standards. This 
includes both generic multi-attribute metrics such as EQ-5D 
utilities as well as disease specific instruments such as the 
ADDQoL 
 
The obvious point that ICER and ISPOR overlook is that if an 
instrument is required then it has to be developed to meet 
fundamental measurement standards 7. The key standards are 
for interval scales: invariance of comparisons and sufficiency 8. 
Unless an instrument is designed from the ground-up to meet 
these standards for a single latent construct then any claims for 
interval scoring, unidimensionality, are wrong. The contribution 
of the Rasch model is to provide the framework for creating 
such instruments. This is not an opinion; it is a question of logic 
in mathematics. If you want to measure temperature, a latent 
single construct, then you create a thermometer. This has been 
the standard in the physical science since the work of Galileo in 
the early 17th century.  So far, health technology assessment 
has ignored these requirements, opting instead for a discipline 
which extols the virtues of building ‘approximate information’ 
imaginary worlds. 
 
Unfortunately, neither ICER nor ISPOR got the memo. We find 
the absurd situation where the most widely used textbook in 
health technology assessment simply assumes, in order to 
create QALYs, that the EQ-5D-3l/5L instruments have interval 
properties 9. They do not. The reason? The EQ-5D-3L was not 
designed to have interval properties. The thought never 
occurred to the developers. It is no good saying that the EQ-5D-
3L/5L have ‘sort of‘ unidimensional characteristics. The fact is 
they do not and should be abandoned, along with the QALY 
notion that depends on them. Necessity, the need to defend 
the QALY measure in lifetime imaginary incremental cost-per-
QALYT worlds, is not the mother of invention.  
 
Although it is now some 60 years since the seminal 
contributions of conjoint simultaneous measurement and the 
Rasch model were proposed, with widespread acceptance in 
the social sciences, the essential contribution of Rasch 
modeling has not been recognized in health technology 
assessment; ICER has certainly not recognized it. ISPOR 
apparently feigns ignorance even though the question of 
measurement as a fundamental requirement in both the 
physical and social sciences is key to any assessment of change 
and hypothesis testing. Failing to recognize this, as Tennant et 
al point out in their contribution to a special section in the 
ISPOR house journal Value in Health (2004):  As long as primitive 
counts and raw scores are routinely mistaken for measures by 
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our colleagues in social, educational and health research, there 
is no hope of their professional activities ever developing into a 
reliable useful science 10 
 
The outcome is the commitment to the creation of imaginary 
world resting on the ‘belief’ in assumptions for 
unidimensionality. Unfortunately, the notion of constructing 
QALYs from utility measures, lacks any scientific status. It is 
pseudoscience. The reason is quite simple: the utility metric 
lacks interval and ratio scale properties. It cannot be used to 
support arithmetical operations (addition, subtraction, 
multiplication, division). At best it can be considered an ordinal 
measure in calibrating response to the symptoms it captures as 
its contribution to the HRQoL family of ordinal measures. That 
is, it can support claims for modal and median values. Nothing 
more. 
 
Any (ordinal) utility will do 
Even if, for the purpose of argument we were to ‘accept’ the 
role of an ordinal utility measure as a ‘proxy’ for an interval 
measure, ICER faces further problems. Although a review of 
previous ICER evidence reports might have suggested that ICER 
has, in practice, adopted the EQ-5D-3L system as the preferred 
metric,  this is put to one side in the evidence report for oral 
semaglutide. Apparently, at a pinch, any multi-attribute ordinal 
system will suffice: The utility values for events modeled from 
the risk equations were drawn from two sources due to a lack of 
a single comprehensive source of health-related quality of life 
inputs. It is also important to point out that the two sources 
used different preference-weighted measures (EQ-5D and 
HUI3), and these two instruments are known to produce slightly 
different utility estimates (emphases added) 3. 
For an organization which sees itself in pole position for 
reference case health technology assessment modeling in the 
US, as the arbiter for state of the art standards in the modeling 
of imaginary worlds, this is a most unfortunate statement. 
There are no references given for this claim, specifically for 
references supporting this claim for the target T2DM target 
population which ICER is attempting to model. Indeed, if ICER is 
to make unsupported claims for utility ‘equivalence’ then it 
should have provided a systematic review of utility metrics in 
the target T2DM population as proposed by ISPOR as ‘good 
practice’. Only then, for those who believe in the construction 
of imaginary worlds on ordinal utilities, could this assumption 
have been justified.  
Indeed, ISPOR has issued practice guidelines that address this 
question with standards proposed for reporting on the choice 
of algorithm and utility metric 11 12. Again, as these guidelines 
were available to ICER, it was surely incumbent upon ICER to 
demonstrate that it had considered and applied these 
guidelines in its choice of utility metrics. 
 
Direct Medical Costs 
If willingness to play thresholds are to be center stage in the 
ICER world, then care also needs to be taken regarding cost 
estimates. If there is no guideline for costs and the projected 
costs of the reference case timeline then there is considerable 
flexibility in the cost assumptions supporting the numerator of 
the incremental cost-per-QALY ratio. This is not clear from the 
ICER reference case, although ICER admits to ‘difficulties’ in 
projecting direct medical cost. One result is that no attempt is 
made to project future drug prices; a somewhat puzzling 
decision given evidence for manufacturers endorsing long-term 
pricing policies. 
 
Choose your disease stage 
If we continue to believe, for the purpose of argument, in the 
relevance of the reference case model meme, the next step in 
the creation of imaginary QALYS is to estimate the time spent 
in different disease stages to which our EQ-5D or other  ordinal 
utilities are to be attached. Again, the options are wide open. 
Different models will generate different times spent in disease 
stages. There is no standard in the health technology meme to 
guide model assumptions. Neither is there any standard to 
guide how serious adverse events with disease stages are to be 
modeled. It is, to use a tired cliché, ‘modeling open season’. 
 
If there are competing models that generate different 
estimates of time spent, and then even with the same utility 
metric, the number of estimated QALYS, as the product of the 
two measures, will differ. ICER needs, therefore, to quite clear 
as to the basis for utility and time spent by disease state 
estimates is ‘by assumption’.  
 
Cost per QALY  
Multiplying time spent in a disease state by an ordinal utility 
metric is, of course, nonsensical. This means that, in addition to 
the choice of model framework and assumptions to fabricate 
claims for time spent in disease stages over the lifetime of a 
hypothetical patient cohort, the next step in the creation of 
lifetime costs per QALY also makes no sense. Certainly, we 
could assume that the ordinal utility is a proxy for an interval 
measure; after all it would be just one more assumption.  
Unfortunately, the ICER model is only one of a possible 
multiverse of models, each generating competing imaginary 
claims. .  
 
The Model Multiverse 
The issue with creating imaginary worlds is that there is no limit 
to the number of imaginary worlds that model builders can 
create. The ICER reference case is quite flexible; any ICER model 
can be challenged. As the imaginary cost-per-QALY paradigm is 
central to the reference case, any number of competing 
imaginary cost-per-QALY claims can be created. Matched to 
threshold values opens the hatches to a prospective tsunami of 
competing imaginary claims. Unlike the UK where NICE will 
contract with imaginary world referees, typically academic 
centers, to act as assessors, ICER acts as its own judge. The ICER 
modelled world, with its foundation in ordinal utilities and 
QALYS that are simply manifest scores, takes center stage. 
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Without deconstruction, its claims for cost-effectiveness are 
taken at face value. 
 
Given ICERs commitment to the imaginary QALY, it is worth 
noting that a previous commentary, following a review of the 
practical impact of modeled cost-per-QALY claims and the 
unlikely event that they would ever be followed up as credible 
and evaluable hypotheses, concluded that: In retrospect, it is 
doubtful, that the great expectations for QALYs could ever be 
realized outside of reference case imaginary worlds, or the 
willingness of decision makers to suspend belief in the standards 
of normal science, and accept lifetime cost-per-QALY claims as 
decision criteria. Unless, therefore, a case can be made for 
short-term and evaluable QALY claims, there seems little scope 
for QALYS, and associated cost-per-QALY claims, as inputs to 
formulary decision making. Perhaps, as Pip d says to Estella, it 
has been ‘a vain hope and an idle pursuit’ 13. After over 30 years 
perhaps we can put QALYs to one side and return to clinically 
and quality specific endpoints  in comparative claims for 
pharmaceutical products in disease and therapeutic areas 14. 
 
Threshold Willingness to Pay 
 The degree of flexibility in choice of assumption in fabricating 
lifetime reference case models has obvious yet important 
implication for ICER value claims. Given the options in utility 
metric, choice of mapping function, estimates of time spent 
stage of disease, modeling of adverse events within disease 
stages and modeled direct medical costs, any claim for price 
discounting or affordability alerts, as in the case of oral 
semaglutide, will be a function of the model assumptions and 
model specification. Apart from the fact that cost-per-QALY 
claims lack credibility given their ordinal basis,  for those who 
wish to continue they have to face the issue that any threshold 
application is dependent on the model structure and 
assumptions.  Different fabricated imaginary worlds will 
produce different pricing and affordability recommendations; 
the ICER model is just one of many. Threshold value claims 
which are, unfortunately, taken at face value by the media 
actually make little sense. 
 
Claims for price discounting will vary depending on the 
components of the incremental cost-per-QALY ratio.  
Competing models, if the same threshold cut-off is applied 
recommendations for price discounting will vary. In fact, claims 
for price discounting will be unique to the imaginary construct. 
Vary the model assumptions and the discounting 
recommendation will change. A $50,000 per QALY threshold for 
one model for a product will result in different value 
judgements for price discounting with other models because 
the imaginary cost-per-QALY estimate will differ. With the same 
threshold, different models will produce different 
recommended price adjustments. If ICER is to subscribe to 
some ‘universal’ application of specific willingness to pay 
thresholds then these must be defined for the model structure 
and assumptions. Ceteris paribus, if the threshold is applied for 
$50,000 per QALY then the utility metric, the EQ-5D-3L for 
example, must be used exclusively, with a specified mapping 
function to generate the utility metric. If there is a literature 
search to locate utility metrics then it must identify utility 
metrics that are comparable if mapping functions are used 
Competing models will yield different pricing conclusions. ICER 
should make this quite clear in media releases. 
 
Diabetes Impact on QoL 
Although this commentary is focused on the ICER model claims 
for oral semaglutide for patients with T2DM, it is of interest to 
consider attempts to date to provide QoL, not HRQoL, 
assessments of the impact of diabetes. The most widely 
reported instrument, for both T1DM and T2DM is the Audit of 
Diabetes Dependent QoL (ADDQoL)15. Initially developed in the 
19909s this has gone through a number of modifications 
without changing its basic structure. It is not the intention here 
to challenge the use of this instrument as a possible profile for 
review with the patient by their treating physician, but to raise 
some concerns that users should be aware of in interpreting 
claims based on the instrument (and spin-offs from the 
instrument). These concerns are to be seen against the 
background of the Rasch model and its adherence to the axioms 
of fundamental measurement. If these are met then, as noted 
above, the derived latent estimate is an interval scale. 
Calibrated change, addition and subtraction, require an interval 
scale. With the Rasch model, we might assume that there exists 
a true zero which then allows the range of arithmetic 
operations. The ADDQoL instrument was not developed with 
fundamental measurement as its lodestar. 
 
Briefly, the ADDQoL takes a patient centric approach to 
assessing QoL impact, promising an individualized measure of 
the impact of QoL.  There are two overview items: (i) “in general 
my present QoL is …and (ii) If I did not have diabetes my QoL 
would be …. Both are 7 response Likert scales. There are a total 
of 13 domain items …”If I did not have diabetes my …. Would 
be …, These are ‘scored’ by assigning integer values to each 
levels (-3 to +3) as arbitrary weights. Summing and averaging 
over these arbitrary weights attached to an ordinal scale yields 
an overall ‘weighted’ ordinal score average with a range from -
9 (maximum negative impact of diabetes) to +3 (maximum 
positive impact of diabetes). 
 
In interpreting these average scores, It is important to 
remember that an ordinal scale, such as the Likert scale, 
‘orders’ the elements of interest but the difference between 
the ‘orders’ or ‘levels’ described in the scale are unknown. The 
difference between an assigned ‘value’ of 2 and 3 for one Likert 
type response for one QoL item cannot be compared to the 
difference between a 2 and a 3 for another item because we 
have no idea of the difference between the numerals 2 and 3 
for each item. Values or weights have been assigned on the 
mistaken belief that they have a common interval value or one 
that has been assigned by attaching arbitrary integer units. This 
is ‘encouraged’ by assigning integer values to response levels; a 
misleading impression that the scale has interval and ratio 
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properties with a true zero. Certainly, you can report modes or 
medians, but nothing else. Arithmetical or statistical operations 
are out, including assigning weights to the item elements 
(weighting an unknown difference) and creating an ‘average’. 
To avoid confusion, it would be more appropriate to assign 
alpha rather than numeric ‘scales’.  
 
However, if the user wishes to interpret these ordinal weighted 
average manifest raw scores as interval scores it is their choice. 
The point to make, if the Rasch model is taken as the gold 
standard for creating QoL instruments, in this case for diabetes 
(but perhaps separate Rasch model instruments for T1DM as 
opposed  to T2DM diabetes) then we can assign interval 
properties, but to a needs based instrument that will be quite 
different from the ADDQoL. For those who may object to 
putting the ADDQoL to one side, after all it has been applied for 
the last 25 years; the case is that the ADDQoL scores have no 
meaning in terms of the axioms of measurement. If the intent 
is to generate from non-physical or psychological constructs 
robust measurement structures then the Rasch model provides 
the appropriate (and well tested) framework. Fitting data to the 
Rash model rather than fitting a model to data provides the 
basis for disease-specific needs based QoL measures. This is 
absent in the ADDQoL instrument. 
 
Public Comments and Response 
Although only a handful of manufacturers and groups 
submitted comments to ICER in response to the release of the 
draft evidence report on 12 September 2019, there were a few 
common themes in these comments that relate to the 
methodological issues raised here in respect of ICER models. 
While there was no direct challenge to ICER on its failure to 
meet standards for evidence based claims and fundamental 
measurement, issues raised were: 
 
 Why did ICER persist in going forward with its 
imaginary modeling on a limited evidence base and 
its continued use of the phrase ‘significant 
uncertainties’? 
 Why a failure to include anticipated price changes, in 
particular when sitagliptin goes generic? 
 Why continue to assume trial based adherence rates? 
 Why introduce utilities from disparate sources 
instead of waiting for US preference utilities to be 
reported? 
 
ICER’s responses are not unexpected. ICER insists on going 
forward to fabricating imaginary worlds even with a limited 
evidence base for its assumptions: 
 
 ….clinicians, patients, and all stakeholders will need 
to make decisions about treatment long before data 
become available that would allow comparisons 
between oral semaglutide and other  options for 
therapy 
 Decision makers must make a well-reasoned decision 
today and our effort is to produce an estimate of 
value for this product with the available data  
 Health care payers must make decisions about 
funding now and cannot hold out for perfect 
information. We appreciate the concern that 
uncertainty and heterogeneity exist, and thus our 
report produces a range of cost-effectiveness 
estimates and thresholds with confidence ranges to 
aid decision makers. 
 ….we feel we have adequately highlighted 
uncertainty. 
 
In addition: 
 
 Including assumptions about price changes is not 
currently the standard in academic or health 
technology assessment agency cost effectiveness 
analyses. In part, this is because it is very difficult to 
predict the pricing landscape years into the future. 
 Trial-based discontinuation rates are included in the 
model estimates. However, we have no long-term 
adherence data for oral semaglutide and thus have 
assumed equal adherence in subsequent model cycles.  
 We acknowledge that there could be differences in 
patient preferences between countries. However, we 
did not identify any other sources for the disutility 
associated with injections in people with Diabetes that 
were specific to the US 
 Furthermore, we utilized multiple sources of utility 
estimates because there was not a single source that 
could provide all of the necessary input values for the 
model. 
 
Affordability 
Although a therapy may meet ICER’s fabricated willingness to 
pay thresholds for cost-effectiveness as determined by the 
imaginary modeled diabetes world, this first hurdle may be 
surmounted only to be halted at the second hurdle: ICER’s 
potential budget impact threshold. 
 
In May 2019, ICER determined that the annual budget impact 
threshold for each individual new molecular entity would be 
$819 million. If projected annual US spending on a specific drug 
exceeds this threshold then ICER will determine the maximum 
number of eligible patients who would be able to receive the 
therapy, at multiple possible pricing points (lower than the 
price deemed  effective in the first hurdle analysis) without 
exceeding the threshold.  
 
The final evidence report concludes that the JAK inhibitors 
budget impact falls within this arbitrary ceiling. Whether 
anyone should take this back-of-the-envelope rationing alert 
seriously is a moot point. To recommend a ceiling for patient 
access to meet a notional budget threshold is to put to one side 
assessed clinical benefits for the individual patient, and 
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whether this merits additional funds being allocated, as well as 
potentially creating waiting lists for access. It is all well and good 
to recommend prior authorization but without recommended 
criteria for approval/refusal, it is a hollow recommendation. 
After all, it would be presumably possible to translate the 
aggregate budget limit into QALYs and estimate the allocation 
of QALYs to each molecular entity and estimate the number of 
patients allowed to utilize the therapy! Unfortunately, this 
would raise the question again of why ordinal and generic 
QALYs are used when the focus is presumably (again) on the 
benefits and harms to patients. 
 
As noted above, ICER recommends a price reduction (from 
WAC) of between 32% and 36% for oral semaglutide. This is 
equivalent, following ICERs lifetime imaginary construct, to an 
annual price of $5,983 to $6,396 for the two thresholds. While 
the precision of these conclusions should not disguise the 
underlying lack of scientific merit in the ICER case, this implies 
limiting patient access (‘trigger policy actions’ – undefined) to 
between 13% and 18% of eligible patients as a switching 
therapy at threshold prices. As an add-on, therapy at the 
threshold price the percentage of patients who could be 
treated without crossing the budget impact threshold is 
between 6.9% and 8.1%.  These claims should not, of course, be 
taken seriously. 
 
Expert Panel Voting 
The last step in the ICER model gestation period is to submit to 
an expert panel of ICER appointees a series of questions 
regarding the model and its value clams. The panel is asked to 
vote on the questions. Their responses are tallied and published 
in the final evidence report.  
 
As this commentary is focused on the reference case model, 
only one question (of the 7 asked) is relevant. This is (Q7) where 
the question is whether the voting panel believes that oral 
semaglutide has a low, intermediate or high long-term value for 
money at current pricing versus ongoing background therapy 
alone at current pricing. As noted in a previous commentary, 
asking this question presupposes that each respondent on the 
panel is familiar with the construction of imaginary worlds, in 
this case microsimulation, and the requirements for 
fundamental measurement. If not, as in the case of health 
system decision makers, the respondents are asked to take 
ICER’s claims at face value. The final evidence report provides 
the panels considered opinions: low 4 votes; intermediate 6 
votes and high 2 votes.  
 
Conclusions: an unfortunate truth 
ICER has not demonstrated that, in the case of T2DM, that the 
EQ-5D health dimensions and response levels are items that are 
relevant in assessing the value T2DM patients attach to their 
experience of oral semaglutide. There is no indication from the 
ICER evidence report that this was even considered. Utilities are 
just ‘dropped in’ with no thought to their relevance, their 
strengths or their limitations. From a patient value perspective, 
therefore, the imposed use of the EQ-5D is of little interest. If 
formulary committees are interested in their value to patients, 
as opposed to clinicians, then the choice of instrument is 
misplaced. The information provided is not only ‘approximate’ 
(whatever that means) but also irrelevant.  
 
The question of how to reflect the patient voice through the 
development of patient-centric measures has been recognized 
for over 40 years. Although ICER seems oblivious to these, it is 
worth pointing out that the patient-centric general health 
question, the Nottingham Health Profile, was developed in the 
mid-to-late 1970s and has been used in a significant number of 
studies and in different language versions 16.  In addition, there 
are now more than 30 disease specific patient-centric 
instruments developed by Galen Research, Manchester, UK 
based on the requirements of RMT.   
 
There is an extensive literature on how a needs-based 
instrument should be developed 17 18. The critical elements are: 
(i) the role of unstructured qualitative interviews with patients 
to identify item selection for the measure covering all aspects 
of the patient’s life; (ii) ensuring that the item selection process 
is independent of specific interventions; (iii) identifying those 
outcomes most relevant to patients; (iv) creating, through 
Rasch analysis, a unidimensional scale supporting a total score; 
and (v) creating a scale that is reliable valid, easy to administer, 
avoids complex language,  complex responses and is able to 
detect change.   
 
Clearly, a patient-centric instrument, which has yet to be 
developed for T2DM, would be a marked improvement in 
capturing the patient voice’ in T2DM over the EQ-5D. It would 
also put to one side the reference case model in focusing on the 
response in real time, through a Phase 4 RCT or a platform of 
T2DM patients.  
 
ICER is apparently not concerned with recognizing the 
importance of fundamental measurement in its claims for 
utility scores. With its preferred EQ-5D-3L multi-attribute utility 
metric, ICER is committed to the use of ordinal scales. This 
undercuts the entire ICER value claim from the cost per QALY 
imaginary or fantasy world. Clearly, any model can generate 
estimates of future imagined time spent in various disease 
stages, with added adverse events as plus utility brownie 
points, with utility scores either from the literature or 
‘constructed’ from expert panels or the modeler’s imagination. 
Given the weights attached to time spent, an aggregate 
estimate of lifetime QALYs is created,. Unfortunately, 
multiplying units of time spent by disease stage (presumably 
cardinal scores) by ordinal utilities for that experience of time 
spent makes no sense. Extending this to cost-per-QALY ratios 
makes no sense either. QALY based claims for oral semaglutide, 
if this argument is accepted, fail to have any meaning. They are 
an artifact that fails standards for fundamental measurement.   
QALYs, as a key element in the health technology assessment 
meme, are resilient. They will continue to be promoted, just as 
Commentary FORMULARY EVALUATIONS 
  
http://z.umn.edu/INNOVATIONS                         2020, Vol. 11, No. 1, Article 10                        INNOVATIONS in pharmacy 
                                                                             DOI: https://doi.org/10.24926/iip.v11i1.2420 
8 
 
relics and indulgencies were after 1517. A belief is not easily 
overturned. The health technology assessment meme, as 
detailed in previous commentaries  is resistant; it has significant 
transcription fidelity and it is a strongly held dogma. Its 
champions, such as ISPOR, will not want to hear that the 
emperor has no clothes. After all, why have manufacturers 
been supporting  consultants to build imaginary worlds for the 
past 30 or more years? This is understandable where the single 
payer health agency mandates constructing imaginary 
reference case world; it is another in the US where there may 
be a greater understanding of the role of fundamental 
measurement and the need for credible and evaluable 
comparative product claims. 
 
It is one thing to encourage ICER and health care decision 
makers to drop claims based on an incremental ordinal and 
nonsensical cost-per-QALY paradigm, it is another to establish 
invariant measurement standards for claims assessment. The 
Part 1 study and other previous commentaries have made the 
case that, if we are concerned with therapy impact assessment 
in target populations, then the assessment of response should 
be specific to the QoL  of that target population. We have to 
return to basics; the sunk capital of technology assessment over 
30 years will be an obstacle. There will also be some degree of 
embarrassment. 
 
Understandably, ICER wants to defend its business model and 
its self-appointed task of issuing evidence reports to, as far as 
possible, coincide with product marketing approval. This 
apparently trumps, to use the current vernacular, questions of 
the strength or otherwise of the evidentiary base to support 
clinical pronouncements, modeled imaginary cost-per-QALY 
claims and constructed affordability alerts. Even though ICER 
believes it has taken ‘adequate’ account of uncertainty and has 
flagged where ‘significant uncertainties’ exist, the point 
remains that ICER has constructed a lifetime model whose 
claims cannot be evaluated and were never intended to be 
evaluated.  Attaching scenario uncertainty claims to an model 
that lacks any scientific credibility is clearly a waste of time. The 
‘well-reasoned’ ICER model is seen, by ICER, as essential (or at 
least an input) to formulary decisions in its construction of an 
unknown future. The future is a mystery, yet ICER has a  
belief that its vision, its belief in the reference  
case meme, is sufficiently ‘approximate’ yet unknowable 
information, for formulary decisions.  The audience must share 
ICER’s faith 19.  
  
Unfortunately, the technology assessment burden that ICER 
has taken upon itself is neither viable nor sustainable. Certainly, 
ICER will persevere; its business case rests upon its self-
appointed role as the arbiter of health technology claims. If the 
ICER reference is the NICE model, then there is no reason it 
should be adopted in the US. This is even more problematic, 
given that the NICE reference case also fails to meet the 
standards of normal science. 
 
Next Steps: Rejecting Imaginary Worlds and Responding to 
ICER 
Manufacturers and other stakeholders in a disease or therapy 
area, who are considering engaging with ICER in its process of 
developing imaginary worlds for its evidence reports, have two 
options. First, they can take the position that the ICER business 
model fails to meet the standards of normal science, inform 
ICER accordingly and reject any engagement or, second, they 
can put to one side concerns over the pseudoscientific nature 
of the ICER model and attempt to engage with ICER to make the 
model ‘more’ relevant to decision makers. Adopting the second 
option can be seen as endorsing the ICER technology 
assessment meme.  The manufacturer may then be placed, if 
the ICER recommendations are for significant price discounts or 
involve affordability alerts, in the position of challenging the 
ICER model, its structure and assumptions. This may involve 
resources to explain to health decision makers the limitations 
of the ICER approach.  The result being the manufacturer 
investing in such an exercise, challenging the ICER imaginary 
world versus competing imaginary worlds. Irrespective of the 
disease area or the therapies chosen for review by the ICER 
team, the model selected for the respective evidence report is 
merely one in a potential multiverse of constructed models. 
While ICER  may claim pole position in imaginary evidence 
constructions, the evidence report model of ICER can be easily 
challenged by other imaginary constructs given the options 
open to change assumptions and the construction of competing 
models within the same reference case  paradigm 20 21 22.  
 
If science is about discovery, then the focus on ‘state of the art’ 
imaginary worlds is both misplaced and misleading. If we are 
concerned with building on the results of RCTs to assess the 
impact in treatment practice of new and competing therapy 
interventions, then this has be both evidence driven and 
reportable to formulary committees in a meaningful time 
frame. It is absurd to substitute imaginary worlds for a program 
designed to add to our knowledge of therapy interventions. 
 
In late 2017, the Program in Social and Administrative 
Pharmacy at the University of Minnesota, published its second 
edition of proposed formulary submission guidelines 23 24. The 
guidelines proposed that if a manufacturer made a submission 
for formulary submission then this should be accompanied by a 
protocol or proposal for how the therapeutic claims were to be 
assessed. These claims could be expressed in purely clinical 
terms or as cost-effectiveness claims, to include HRQoL 
 
The recommended next step , after putting ICER to one side, is 
to focus on the issue of evaluating patients’ needs in T2DM 
through developing a disease specific instrument to evaluate 
response to therapy. Not the measurement of functions and 
symptoms, but a need-based measure. This will set the stage 
for a discovery-focused research program capturing the patient 
voice; a program that meets the standards of normal science.  
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